Navigation Links
Pfenex Inc. Establishes Reagent Protein Distribution Agreement With Cedarlane Corporation
Date:8/24/2010

SAN DIEGO, Aug. 24 /PRNewswire/ -- Pfenex Inc. and Cedarlane today announced that they have entered into a non-exclusive distribution agreement. Cedarlane will market and distribute high value reagent proteins produced by Pfenex to researchers in Canada and the United States. Among the products initially distributed will be vaccine carrier proteins such as CRM197 and Cholera Toxin B and cell culture related growth factors including G-CSF and Interferon beta 1-b. New products which are developed by Pfenex will be added to the Cedarlane catalogue upon launch.

"We are pleased to establish this distribution relationship with Cedarlane," stated Patrick K. Lucy, Vice President, Business Development at Pfenex Inc. "Leveraging the Pfenex Expression Technology™ platform, we are now producing and making available complex reagent proteins to meet the needs of the biotech R&D and clinical development community. As Pfenex grows its reagent proteins business, we welcome the opportunity to work with world class distributors such as Cedarlane to enable placing Pfenex products in the hands of life science researchers around the world."

"CEDARLANE is proud to add Pfenex Inc. products to its extensive portfolio," said John Course, CEDARLANE Vice President. "Canadian scientists have an even greater opportunity to consolidate their ordering from a long list of high-quality suppliers of scientific reagents." Key components of the CEDARLANE mission are to provide quality products, assure the highest in customer satisfaction and respond to the dynamic needs of every research community.

About Pfenex Inc.

Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com

About CEDARLANE

In business since 1957 and incorporated in 1975, CEDARLANE is a 100% Canadian Corporation and a leading supplier of research reagents in North America and worldwide. The company is ISO 9001 accredited and ISO 13485 certified.

www.pfenex.com

www.cedarlanelabs.com


'/>"/>
SOURCE Pfenex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
2. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
3. Mach 7 Technologies Establishes New Headquarters in Burlington, VT
4. Renhuang Appoints New Director and Establishes Nominating and Compensation Committee
5. BD Establishes $1.2 Million Fund for Haiti Earthquake Relief Efforts
6. FUJIFILM Establishes Medical Informatics Organization
7. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
8. Pharmaxis Establishes Named Patient Program for Bronchitol
9. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
10. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
11. New England Biolabs Launches NEBNext™ Quick DNA Sample Prep Reagent Sets for Use With Roche/454 Next Generation Sequencing Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
Breaking Medicine News(10 mins):